Neurogene Stock (NASDAQ:NGNE)
Previous Close
$33.14
52W Range
$6.88 - $74.49
50D Avg
$23.52
200D Avg
$18.93
Market Cap
$488.96M
Avg Vol (3M)
$180.06K
Beta
1.59
Div Yield
-
NGNE Company Profile
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.